-
1دورية أكاديمية
المؤلفون: Raharja, Antony, Arkir, Zehra, Rinaldi, Giulia, Tsakok, Teresa, Dasandi, Tejus, Guard, Sarah, McGuire, Arlene, Pink, Andrew E., Woolf, Richard, Barker, Jonathan N., Smith, Catherine H., Mahil, Satveer K.
المساهمون: Psoriasis Association, NIHR BRC, National Institute for Health and Care Research
المصدر: Journal of Investigative Dermatology ; volume 143, issue 9, page 1708-1716.e4 ; ISSN 0022-202X
مصطلحات موضوعية: Cell Biology, Dermatology, Molecular Biology, Biochemistry
الإتاحة: https://doi.org/10.1016/j.jid.2023.01.033Test
https://api.elsevier.com/content/article/PII:S0022202X23001604?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0022202X23001604?httpAccept=text/plainTest -
2مؤتمر
المؤلفون: Samaan, Mark, Cunningham, Georgina, Lim, Samuel, Dawson, Patrick, Kottoor, Sherine Hermangild, Bheekhun, Zareen, Odukwe, Sopuluchukwu, Raymode, Parizade, Lee, Emma, Balachandran, Senthuran, Anderson, Simon, Mawdsley, Joel, Ray, Shuvra, Powell, Nicholas, Dart, Robin, Rawstron, Krystal, Arkir, Zehra, Irving, Peter
المصدر: Poster Presentations
-
3دورية أكاديمية
المؤلفون: Chanchlani, Neil, Lin, Simeng, Chee, Desmond, Hamilton, Benjamin, Nice, Rachel, Arkir, Zehra, Bewshea, Claire, Cipriano, Bessie, Derikx, Lauranne A. A. P., Dunlop, Allan, Greathead, Louise, Griffiths, Rachel L., Ibraheim, Hajir, Kelleher, Peter, Kok, Klaartje B., Lees, Charlie W., MacDonald, Jonathan, Sebastian, Shaji, Smith, Philip J., McDonald, Timothy J., Irving, Peter M., Powell, Nick, Kennedy, Nicholas A., Goodhand, James R., Ahmad, Tariq
المصدر: Chanchlani , N , Lin , S , Chee , D , Hamilton , B , Nice , R , Arkir , Z , Bewshea , C , Cipriano , B , Derikx , L A A P , Dunlop , A , Greathead , L , Griffiths , R L , Ibraheim , H , Kelleher , P , Kok , K B , Lees , C W , MacDonald , J , Sebastian , S , Smith , P J , McDonald , T J , Irving , P M , Powell , N , Kennedy , ....
مصطلحات موضوعية: adalimumab, biologic, CLARITY, COVID-19, immunosuppression, inflammatory bowel disease, infliximab, vaccination, vedolizumab
الوصف: BACKGROUND AND AIMS: Infliximab attenuates serological responses to SARS-CoV-2 infection. Whether this is a class effect, or if anti-tumour necrosis factor [anti-TNF] level influences serological responses, remains unknown. METHODS: Seroprevalence and the magnitude of SARS-CoV-2 nucleocapsid antibody responses were measured in surplus serum from 11 422 (53.3% [6084] male; median age 36.8 years) patients with immune-mediated inflammatory diseases, stored at six therapeutic drug monitoring laboratories between January 29 and September 30, 2020. Data were linked to nationally held SARS-CoV-2 PCR results to July 11, 2021. RESULTS: Rates of PCR-confirmed SARS-CoV-2 infection were similar across treatment groups. Seroprevalence rates were lower in infliximab- and adalimumab- than vedolizumab-treated patients (infliximab: 3.0% [178/5893], adalimumab: 3.0% [152/5074], vedolizumab: 6.7% [25/375], p = 0.003). The magnitude of SARS-CoV-2 reactivity was similar in infliximab- vs adalimumab-treated patients (median 4.30 cut-off index [COI] [1.94-9.96] vs 5.02 [2.18-18.70], p = 0.164), but higher in vedolizumab-treated patients (median 21.60 COI [4.39-68.10, p < 0.004). Compared to patients with detectable infliximab and adalimumab drug levels, patients with undetectable drug levels [<0.8 mg/L] were more likely to be seropositive for SARS-CoV-2 antibodies. One-third of patients who had PCR testing prior to antibody testing failed to seroconvert, all were treated with anti-TNF. Subsequent positive PCR-confirmed SARS-CoV-2 was seen in 7.9% [12/152] of patients after a median time of 183.5 days [129.8-235.3], without differences between drugs. CONCLUSION: Anti-TNF treatment is associated with lower SARS-CoV-2 nucleocapsid seroprevalence and antibody reactivity when compared to vedolizumab-treated patients. Higher seropositivity rates in patients with undetectable anti-TNF levels support a causal relationship, although confounding factors, such as combination therapy with a immunomodulator, may have influenced the results.
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1093/ecco-jcc/jjab153Test
https://kclpure.kcl.ac.uk/portal/en/publications/1fd256f3-70ad-4c8d-b7f5-eed520031c42Test
https://kclpure.kcl.ac.uk/ws/files/170412073/Adalimumab_and_Infliximab_Impair_CHANCHLANI_Published_online_2_Sept_21_GOLD_VoR_CC_BY_NC_.pdfTest
http://www.scopus.com/inward/record.url?scp=85126490511&partnerID=8YFLogxKTest -
4دورية أكاديمية
المؤلفون: Luber, Raphael P., O'Neill, Rhona, Singh, Sukhpreet, Sharma, Esha, Cunningham, Georgina, Honap, Sailish, Meade, Susanna, Ray, Shuvra, Anderson, Simon H., Mawdsley, Joel, Sanderson, Jeremy D., Samaan, Mark A., Arkir, Zehra, Irving, Peter M.
المصدر: Luber , R P , O'Neill , R , Singh , S , Sharma , E , Cunningham , G , Honap , S , Meade , S , Ray , S , Anderson , S H , Mawdsley , J , Sanderson , J D , Samaan , M A , Arkir , Z & Irving , P M 2021 , ' An observational study of switching infliximab biosimilar : no adverse impact on inflammatory bowel disease control or drug levels with first or second switch ' , Alimentary Pharmacology and Therapeutics , vol. 54 , no. 5 ....
الوصف: Background: Biologics account for a significant cost in inflammatory bowel disease (IBD) management; however, switching from infliximab originator to its biosimilars has enabled cost saving without compromising disease control. The effects on IBD activity and infliximab trough levels of a second switch to another biosimilar are, however, uncertain. Aims: To assess the effects on disease activity and infliximab trough levels associated with switching from infliximab biosimilar CT-P13 to another biosimilar SB2 and compare outcomes in those switching for the first and second time. Methods: IBD patients on CT-P13, including some previously switched from originator, were prospectively followed during a switch to SB2. C-reactive protein (CRP), trough infliximab level and clinical disease activity indices were collected at baseline, Infusion 3 or 4 (‘early’ after switch), and 1 year. Results: One hundred eighty-six patients (n = 99 second switch) on stable infliximab dosing underwent switching. Compared with baseline, there was no significant change in CRP, clinical disease activity scores or median trough infliximab level at the early time point among first-switch (baseline vs early: 5.7 vs 6.6 µg/mL, P = 0.05) and second-switch (4.3 vs 4.9 µg/mL, P = 0.07) patients nor at 1 year (median infliximab trough levels, baseline vs 1 year, in first-switch [5.7 vs 5.7 µg/mL, P = 0.37] and second-switch [4.3 vs 4.7 µg/mL, P = 0.06] patients). The proportion of patients in clinical remission did not significantly change at the early (92% vs 91% at baseline, P = 0.75) or 1 year (95% vs 91% at baseline, P = 0.16) time points. There was no significant difference in time to loss of response between patients switching for the first or second time (P = 0.69). Conclusions: Switching from one infliximab biosimilar to another had no adverse impact on infliximab trough levels, and clinical and biochemical disease activity, regardless of whether switching for the first or second time.
الإتاحة: https://doi.org/10.1111/apt.16497Test
https://kclpure.kcl.ac.uk/portal/en/publications/194c2446-89aa-40af-a1fe-9bba16e01d6eTest
http://www.scopus.com/inward/record.url?scp=85109103844&partnerID=8YFLogxKTest -
5دورية أكاديمية
المؤلفون: Chanchlani, Neil, Lin, Simeng, Chee, Desmond, Hamilton, Benjamin, Nice, Rachel, Arkir, Zehra, Bewshea, Claire, Cipriano, Bessie, Derikx, Lauranne A A P, Dunlop, Allan, Greathead, Louise, Griffiths, Rachel L, Ibraheim, Hajir, Kelleher, Peter, Kok, Klaartje B, Lees, Charlie W, MacDonald, Jonathan, Sebastian, Shaji, Smith, Philip J, McDonald, Timothy J, Irving, Peter M, Powell, Nick, Kennedy, Nicholas A, Goodhand, James R, Ahmad, Tariq
المصدر: Journal of Crohn's and Colitis ; volume 16, issue 3, page 389-397 ; ISSN 1873-9946 1876-4479
الوصف: Background and Aims Infliximab attenuates serological responses to SARS-CoV-2 infection. Whether this is a class effect, or if anti-tumour necrosis factor [anti-TNF] level influences serological responses, remains unknown. Methods Seroprevalence and the magnitude of SARS-CoV-2 nucleocapsid antibody responses were measured in surplus serum from 11 422 (53.3% [6084] male; median age 36.8 years) patients with immune-mediated inflammatory diseases, stored at six therapeutic drug monitoring laboratories between January 29 and September 30, 2020. Data were linked to nationally held SARS-CoV-2 PCR results to July 11, 2021. Results Rates of PCR-confirmed SARS-CoV-2 infection were similar across treatment groups. Seroprevalence rates were lower in infliximab- and adalimumab- than vedolizumab-treated patients (infliximab: 3.0% [178/5893], adalimumab: 3.0% [152/5074], vedolizumab: 6.7% [25/375], p = 0.003). The magnitude of SARS-CoV-2 reactivity was similar in infliximab- vs adalimumab-treated patients (median 4.30 cut-off index [COI] [1.94–9.96] vs 5.02 [2.18–18.70], p = 0.164), but higher in vedolizumab-treated patients (median 21.60 COI [4.39–68.10, p < 0.004). Compared to patients with detectable infliximab and adalimumab drug levels, patients with undetectable drug levels [<0.8 mg/L] were more likely to be seropositive for SARS-CoV-2 antibodies. One-third of patients who had PCR testing prior to antibody testing failed to seroconvert, all were treated with anti-TNF. Subsequent positive PCR-confirmed SARS-CoV-2 was seen in 7.9% [12/152] of patients after a median time of 183.5 days [129.8–235.3], without differences between drugs. Conclusion Anti-TNF treatment is associated with lower SARS-CoV-2 nucleocapsid seroprevalence and antibody reactivity when compared to vedolizumab-treated patients. Higher seropositivity rates in patients with undetectable anti-TNF levels support a causal relationship, although confounding factors, such as combination therapy with a immunomodulator, may have influenced ...
الإتاحة: https://doi.org/10.1093/ecco-jcc/jjab153Test
https://academic.oup.com/ecco-jcc/article-pdf/16/3/389/42893787/jjab153.pdfTest -
6مؤتمر
المؤلفون: Samaan, Mark A, Cunningham, Georgina, Tamilarasan, Aravind Gokul, Rawstron, Krystal, Hawash, Karim, Beltran, Luisa, Koumoutsos, Ioannis, Ray, Shuvra, Mawdsley, Joel, Anderson, Simon H, Sanderson, Jeremy D, Arkir, Zehra, Irving, Peter M
المصدر: Inflammatory Bowel Disease
-
7مؤتمر
المؤلفون: Tamilarasan, Aravind Gokul, Guerrero, Antonio, Arias, Laura, Burns, Megan, Arkir, Zehra, Irving, Peter
المصدر: Posters
-
8
-
9دورية أكاديمية
المؤلفون: Langford, Thomas, Arkir, Zehra, Chalkidou, Anastasia, Goddard, Kate, Kaftantzi, Lamprini, Samaan, Mark, Irving, Peter
المصدر: Langford , T , Arkir , Z , Chalkidou , A , Goddard , K , Kaftantzi , L , Samaan , M & Irving , P 2018 , ' The Clinical and Cost-Effectiveness of 4 Enzyme-Linked Immunosorbent Assay Kits for Monitoring Infliximab in Crohn Disease Patients : Protocol for a Validation Study ' , JMIR research protocols , vol. 7 , no. 10 , e11218 . https://doi.org/10.2196/11218Test
مصطلحات موضوعية: Anti-TNF, Antidrug antibodies, Crohn’s disease, ELISA, Inflammatory bowel disease, Infliximab, Therapeutic drug monitoring
الوصف: Background: Currently, treatment decisions for people with Crohn disease are based on clinical judgment and trial and error. Consequently, people may continue to receive high drug dosages and experience unnecessary toxicity when it is possible to reduce or discontinue without a detrimental effect on clinical outcomes. Therapeutic drug monitoring (TDM) involves regularly testing blood samples for drug and antibody levels that could help clinicians identify the optimal treatment strategy and pre-empt treatment failure. However, heterogeneity in the assays can lead to a discrepancy in results and difficulties in decision-making. Standardization of the kits, and therefore results, would allow clinicians to optimize the use of biologics. Currently, there is also a lack of evidence for the cost-effectiveness of TDM using commercial test kits. Objective: This study aims to analyze the clinical and cost-effectiveness of 4 commercial enzyme-linked immunosorbent assay (ELISA) kits (LISA TRACKER, IDKmonitor, Promonitor, and RIDASCREEN) to generate evidence which could support a recommendation for wider adoption in the National Health Service. Methods: We propose to carry out a prospective-retrospective predictive biomarker validation study using the blood samples and clinical/utilization data collected during the ongoing SPARE trial (NCT02177071). A total of 200 stored samples from people with Crohn's disease who respond to treatment with infliximab will be used along with clinical and cost data from the trial. We will investigate the relationship between the drug and antidrug antibody levels with the main clinical outcomes (relapse rate at 2 years and time spent in remission), as well as resource utilization and quality of life. Results: Funding is being sought to conduct this research. Conclusions: This is the first study to compare the 4 ELISA kits for monitoring infliximab in patients with Crohn disease. It aims to address the uncertainties in the potential benefits of using the technologies for TDM.
الإتاحة: https://doi.org/10.2196/11218Test
https://kclpure.kcl.ac.uk/portal/en/publications/da913e35-9410-407e-8b94-10d74230cbffTest
http://www.scopus.com/inward/record.url?scp=85102368064&partnerID=8YFLogxKTest -
10
المؤلفون: Claire Bewshea, James R Goodhand, Peter Kelleher, Nick Powell, Rachel L Griffiths, Nicholas A. Kennedy, Philip J Smith, Shaji Sebastian, Arkir Zehra, Bessie Cipriano, Desmond Chee, Louise Greathead, Benjamin Hamilton, Simeng Lin, Rachel Nice, Lauranne A A P Derikx, Neil Chanchlani, Hajir Ibraheim, Peter M. Irving, Klaartje Kok, Charlie W. Lees, Jonathan Macdonald, Timothy J. McDonald, Allan Dunlop, Tariq Ahmad
المصدر: Journal of Crohn's and Colitis, 16, 3, pp. 389-397
Journal of Crohn's & Colitis
Journal of Crohn's and Colitis, 16, 389-397
Chanchlani, N, Lin, S, Chee, D, Hamilton, B, Nice, R, Arkir, Z, Bewshea, C, Cipriano, B, Derikx, L A A P, Dunlop, A, Greathead, L, Griffiths, R L, Ibraheim, H, Kelleher, P, Kok, K B, Lees, C W, MacDonald, J, Sebastian, S, Smith, P J, McDonald, T J, Irving, P M, Powell, N, Kennedy, N A, Goodhand, J R & Ahmad, T 2022, ' Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses : Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients ', Journal of Crohn's & colitis, vol. 16, no. 3, pp. 389-397 . https://doi.org/10.1093/ecco-jcc/jjab153Testمصطلحات موضوعية: Male, TNF, Gastroenterology, Serology, Seroepidemiologic Studies, adalimumab, skin and connective tissue diseases, immunosuppression, biology, medicine.diagnostic_test, General Medicine, Eccojc/1020, Original Article, Drug Monitoring, Antibody, Life Sciences & Biomedicine, biologic, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], medicine.drug, vedolizumab, Adult, medicine.medical_specialty, Combination therapy, MATURATION, Vedolizumab, DEFICIENT, inflammatory bowel disease, Internal medicine, Adalimumab, medicine, Humans, Seroprevalence, AcademicSubjects/MED00260, Biological Products, Science & Technology, Gastroenterology & Hepatology, SARS-CoV-2, business.industry, COVID-19, 1103 Clinical Sciences, vaccination, Inflammatory Bowel Diseases, Infliximab, ALPHA, Therapeutic drug monitoring, CLARITY, Antibody Formation, biology.protein, Tumor Necrosis Factor Inhibitors, infliximab, business, INFLAMMATORY-BOWEL-DISEASE
الوصف: Background and Aims Infliximab attenuates serological responses to SARS-CoV-2 infection. Whether this is a class effect, or if anti-tumour necrosis factor [anti-TNF] level influences serological responses, remains unknown. Methods Seroprevalence and the magnitude of SARS-CoV-2 nucleocapsid antibody responses were measured in surplus serum from 11 422 (53.3% [6084] male; median age 36.8 years) patients with immune-mediated inflammatory diseases, stored at six therapeutic drug monitoring laboratories between January 29 and September 30, 2020. Data were linked to nationally held SARS-CoV-2 PCR results to July 11, 2021. Results Rates of PCR-confirmed SARS-CoV-2 infection were similar across treatment groups. Seroprevalence rates were lower in infliximab- and adalimumab- than vedolizumab-treated patients (infliximab: 3.0% [178/5893], adalimumab: 3.0% [152/5074], vedolizumab: 6.7% [25/375], p = 0.003). The magnitude of SARS-CoV-2 reactivity was similar in infliximab- vs adalimumab-treated patients (median 4.30 cut-off index [COI] [1.94–9.96] vs 5.02 [2.18–18.70], p = 0.164), but higher in vedolizumab-treated patients (median 21.60 COI [4.39–68.10, p Conclusion Anti-TNF treatment is associated with lower SARS-CoV-2 nucleocapsid seroprevalence and antibody reactivity when compared to vedolizumab-treated patients. Higher seropositivity rates in patients with undetectable anti-TNF levels support a causal relationship, although confounding factors, such as combination therapy with a immunomodulator, may have influenced the results.
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c08447d7329ab51228946a10f8ee899Test
